Financial Performance - The company's operating revenue for 2021 was CNY 529,615,447.55, representing an increase of 8.05% compared to CNY 490,164,744.19 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 68,507,883.04, a decrease of 25.53% from CNY 91,988,592.72 in 2020[18]. - The net cash flow from operating activities was CNY 48,149,282.18, down 24.34% from CNY 63,639,874.30 in the previous year[18]. - The basic earnings per share for 2021 was CNY 1.05, a decline of 31.37% compared to CNY 1.53 in 2020[18]. - The total operating revenue for 2021 was CNY 529,615,447.55, representing an increase of 8.05% compared to CNY 490,164,744.19 in 2020[46]. - The core product, Sodium Acetate Ringer's Injection, generated sales revenue of CNY 465,358,327.89, accounting for 87.87% of total revenue, with a year-on-year growth of 1.46%[46]. - The sales revenue from Cefotaxime Sodium Injection reached CNY 64,244,978.07, making up 12.13% of total revenue, with a significant increase of 103.98% compared to the previous year[48]. - The total operating costs for 2021 were CNY 60,327,111.01, reflecting a year-on-year increase of 35.91%[48]. - The company reported a total R&D investment of ¥24,067,136.11 in 2021, accounting for 4.54% of its operating revenue, a decrease from 4.76% in 2020[60]. Assets and Liabilities - Total assets at the end of 2021 reached CNY 851,423,622.82, an increase of 129.49% from CNY 371,006,145.17 at the end of 2020[18]. - The net assets attributable to shareholders increased by 227.16% to CNY 792,918,557.15 from CNY 242,361,001.66 in 2020[18]. - The company reported a decrease in accounts receivable by 15.26% to ¥98,290,746.40, indicating improved cash collection efficiency[67]. - The company’s cash and cash equivalents increased to ¥610,930,333.60 by the end of 2021, representing 71.75% of total assets, up from 28.20% at the beginning of the year[67]. Market and Product Development - The company's core product, Sodium Acetate Injection, achieved a domestic market share of nearly 90% in the first half of 2021[32]. - The company has developed a new gel colloid production technology platform, which aims to reduce production costs and improve product quality[33]. - The company is facing risks related to the national and local volume-based procurement policies, which could affect pricing and sales volume of its core products[31]. - The company has several new product developments, including sodium bicarbonate injection and venlafaxine sustained-release capsules, aimed at expanding its product line in the plasma substitutes and psychiatric markets[58]. - The company plans to accelerate the layout of raw material drug production and expand into emergency drugs, pediatric drugs, and psychiatric drugs[84]. - The company is actively developing traditional Chinese medicine products in response to national policies encouraging TCM development[84]. Research and Development - The company has 64 R&D personnel, accounting for 21.40% of total employees, indicating a strong focus on research and development[44]. - The number of R&D personnel decreased by 4.48% to 64 in 2021, representing 21.40% of the total workforce[60]. - The company is heavily investing in R&D, aligning its plans with long-term development strategies to enhance innovation capabilities[44]. - The company holds 48 patents, including 10 invention patents, and is in the process of applying for 8 additional invention patents[45]. Governance and Compliance - The company has established a performance evaluation incentive system linking management compensation to business performance, with a transparent hiring process for senior management[93]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors through designated channels[93]. - The company maintains independence from its controlling shareholders in business, personnel, assets, organization, and finance, ensuring autonomous operations[95][96]. - The company has established a robust financial and accounting management system, ensuring independent financial decision-making[96]. - The company has not faced any disciplinary actions from regulatory bodies regarding internal control issues during the reporting period[94]. Cash Dividends and Profit Distribution - The company implemented a stable profit distribution policy, prioritizing cash dividends, with a minimum cash distribution of 10% of the distributable profit for the year[125]. - The cash dividend for the year was set at 6.25 CNY per 10 shares, totaling 50,000,000 CNY, which represents 100% of the total profit distribution[132]. - The company plans to prioritize cash dividends, ensuring that at least 10% of the distributable profits for the year are allocated as cash dividends, provided the company is profitable and has accumulated undistributed profits[158]. - The company will adopt a combination of cash and stock dividends for profit distribution, depending on its cash flow and business growth[158]. Corporate Social Responsibility - The company actively fulfilled its corporate social responsibility by donating school supplies to underprivileged students in April 2021[145]. - The company reported no environmental violations or administrative penalties during the reporting period, adhering strictly to environmental protection laws[142]. - The company has not faced any significant environmental issues and has taken measures to comply with relevant environmental regulations[142]. Future Outlook - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[100]. - New product launches are expected to contribute an additional 300 million CNY in revenue in 2022[100]. - The company has provided a positive outlook for 2022, projecting a revenue growth of 30% based on new product launches and market expansion strategies[164]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million CNY allocated for this purpose[153].

Financial Performance - The company's operating revenue for Q3 2021 was ¥152,487,333.59, a decrease of 1.63% compared to the same period last year, while year-to-date revenue increased by 19.73% to ¥396,422,129.81[3] - Net profit attributable to shareholders for Q3 2021 was ¥12,230,327.97, down 15.12% year-on-year, with a year-to-date net profit of ¥49,344,309.41, reflecting an 18.68% decrease[3] - The basic earnings per share for Q3 2021 was ¥0.20, a decline of 16.67% compared to the same period last year, with year-to-date earnings per share at ¥0.82, down 18.81%[3] - The net profit for Q3 2021 was CNY 47,286,377.81, a decrease of 19.5% compared to CNY 58,792,608.79 in Q3 2020[19] - The total profit for the period was CNY 53,319,278.12, down from CNY 66,781,382.09, reflecting a decline of 20.2% year-over-year[19] - Basic and diluted earnings per share were both CNY 0.82, compared to CNY 1.01 in the same quarter last year, indicating a decrease of 18.8%[20] - The total comprehensive income attributable to the parent company was CNY 49,344,309.41, down from CNY 60,680,371.19, reflecting a decline of 18.7%[20] Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥881,801,697.35, representing a significant increase of 137.68% compared to the end of the previous year[3] - Total assets as of September 30, 2021, were ¥881,801,697.35, compared to ¥371,006,145.17 at the end of 2020, indicating a growth of 137.5%[17] - The company's total liabilities decreased to ¥111,741,881.49 from ¥130,282,379.57, a reduction of 14.1%[16] - The company's total liabilities stood at CNY 130,282,379.57, with non-current liabilities including lease liabilities of CNY 1,967,645.99[28] - Shareholders' equity totaled CNY 240,723,765.60, with retained earnings of CNY 116,373,429.76[28] - The equity attributable to shareholders increased to ¥773,754,983.52 from ¥242,361,001.66, reflecting a growth of 219.5%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥39,546,864.33, an increase of 12.60%[3] - Cash flow from operating activities generated a net amount of CNY 39,546,864.33, an increase of 12.3% from CNY 35,120,925.99 in the previous year[21] - Cash and cash equivalents increased significantly to ¥637,379,375.20 from ¥104,491,944.61, representing a growth of 510.5%[14] - Cash and cash equivalents at the end of the period totaled CNY 637,379,375.20, significantly up from CNY 80,425,679.46 at the end of the same quarter last year[23] - The company reported cash inflow from financing activities of CNY 537,803,960.00, a substantial increase compared to CNY 41,080,000.00 in the previous year[23] - The cash outflow for investment activities was CNY 3,993,603.56, a decrease from CNY 49,659,358.80 in the same period last year, indicating a reduction in investment spending[23] - The company experienced a net increase in cash and cash equivalents of CNY 532,887,430.59 during the period, compared to a decrease of CNY 15,163,804.57 in the previous year[23] Inventory and Costs - The company experienced a 50.81% decrease in inventory compared to the beginning of the year, mainly due to reduced stock of injectable cefotaxime sodium[8] - Inventory levels decreased to ¥7,294,220.05 from ¥14,827,808.31, a decline of 50.8%, suggesting improved inventory management[15] - Total operating costs amounted to ¥346,559,133.52, up 19.3% from ¥290,473,683.25 year-on-year[17] Research and Development - Research and development expenses for the period were ¥17,360,705.80, slightly up from ¥16,420,025.30, indicating a focus on innovation[17] Accounting and Standards - The company has implemented new leasing standards affecting the financial statements, indicating a shift in accounting practices[24] - The company adopted the new lease accounting standard, resulting in an increase of CNY 1,967,645.99 in both right-of-use assets and lease liabilities[29] - The third quarter report was not audited, indicating preliminary financial data[29] Market Strategy - The company aims to expand its market presence and enhance product offerings, although specific details on new products or technologies were not disclosed in the report[17] - The company has not disclosed any new product developments or market expansion strategies in the current report[28]